November isn't half-finished, and it's already shaping up to be an exciting month for pharmaceutical companies that market weight-management drugs. On Nov. 8, the active ingredient in Eli Lilly's (NYSE: LLY) type 2 diabetes treatment Mounjaro earned approval from the Food and Drug Administration (FDA) for chronic weight management under a new brand name, Zepbound.

Just a few days later, Novo Nordisk (NYSE: NVO) released positive results from a closely watched clinical trial with its weight-management drug Wegovy.

Image source: Getty Images.

Continue reading

Source Fool.com